Yes 50% below that median target, the only analyst pricing...

Yes 50% below that median target, the only analyst pricing Vitiligo is near $50, and looking very undervalued especially when compared to the best comparison stock in Disc and many/most other Biotechs. Here's what the Clinuvel board of directors said about this crazy undervaluation, and also what the company said in a recent newsletter regarding the share buyback (underline mine):

"Board of Directors view current market capitalisation as decoupled from the Company's value". PW said on the same release "Given expected earnings, underlying growth in existing and new porphyria markets, current cash reserves, and projected expenses over the next 12 months, redistribution of capital to shareholders through a buy-back program is appropriate".

"We have chosen the moment of a repurchase as first clinical results for 2024 are published, and we will keep at it until those who gamble against the Company have understood the message.Given the expected future cash flows, we are in the position to prolong the program when required, since Board and management do not believe that market value has reflected the Company's performance in recent months. To those shareholders who have proven supportive, we have waited for the right moment to strike on your behalf."

"The share buy-back further increases the relative percentage of ownership for our owners, and thereby compounds CLINUVEL'S strategy to minimise dilution. With 1,500,000 shares (or approximately 3% of the outstanding share capital) to be repurchased, we hold a longer-term view on capital management without jeopardising plans to reinvest and expand the Company."

"The first trading days after the buy-back announcement on 14 March dispelled the myth that the share price is reflective of performance only"

Just get moving with the buyback, anything under $30 is a comparative bargain, and maybe back it up with some executive buying to show that everyone internal is aligned with long suffering investors who believe in the company strategy but have questions when the share price is at 5 year lows and new investment is just not happening much despite money being spent on Michelin catered Soirees and three IR experts on three continents. Really indefensible in my opinion that they continue to allow low volume manipulation to continue unchallenged, "those who gamble against the company" have not been challenged at all on shareholder behalf despite lots of words. Open shorts very high at 5.8% in a stock that is extremely tightly held (shareholders believe in the molecule), share price at 5 year lows, markets at ATHs (contrary to CEO words in last newsletter), great for new buyers, ordinary for long termers.

All IMO DYOR